EP0785211A1 — New substituted 19-nor-pregnane derivatives
Assigned to Laboratoire Theramex SAM · Expires 1997-07-23 · 29y expired
What this patent protects
The invention relates to compounds of the formula : wherein : each of R 1 and R 2 is hydrogen or a (C 1 -C 6 )alkyl, R 1 and R 2 being not simultaneously hydrogen ; R 3 is hydrogen, a (C 1 -C 6 )alkyl or a (C 1 -C 6 )alkoxy ; R 4 is hydrogen, a (C 1 -C 6 )alk…
USPTO Abstract
The invention relates to compounds of the formula : wherein : each of R 1 and R 2 is hydrogen or a (C 1 -C 6 )alkyl, R 1 and R 2 being not simultaneously hydrogen ; R 3 is hydrogen, a (C 1 -C 6 )alkyl or a (C 1 -C 6 )alkoxy ; R 4 is hydrogen, a (C 1 -C 6 )alkyl or a group -COR 6 where R 6 is a (C 1 -C 6 )alkyl ; R 5 is hydrogen or a (C 1 -C 6 )alkyl ; n is zero or one ; X is oxygen or an hydroxyimino group ; and the dotted line may represent a double bond ; provided that when n = 0, R 3 is hydrogen only if both R 1 and R 2 are a (C 1 -C 6 )alkyl, and to pharmaceutical compositions containing them. These compounds are potent progestogens which are devoid of residual androgenic activity.
Drugs covered by this patent
- Estrace (ESTRADIOL) · Pfizer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.